# | Filing Date | Period End Date | Type | Report Link |
---|---|---|---|---|
No Data found |
# | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
---|
Foundation Medicine, Inc. today announced a collaboration to develop Foundation Medicine's RNA platform as a companion diag...
Needham analyst Ami Fadia maintains Merus (NASDAQ:MRUS) with a Buy and lowers the price target from $92 to $85.
Merus (NASDAQ:MRUS) reported quarterly losses of $(0.81) per share which missed the analyst consensus estimate of $(0.76) by 6....
Canaccord Genuity analyst John Newman maintains Merus (NASDAQ:MRUS) with a Buy and maintains $67 price target.
Needham analyst Ami Fadia reiterates Merus (NASDAQ:MRUS) with a Buy and maintains $92 price target.
Citigroup analyst Yigal Nochomovitz maintains Merus (NASDAQ:MRUS) with a Buy and raises the price target from $70 to $93.
B of A Securities analyst Tazeen Ahmad maintains Merus (NASDAQ:MRUS) with a Buy and maintains $76 price target.